New Drug Targets Epigenetic Mark, May Help Treat Rare Cancer

June 23, 2020 Danton Ivanochko

In 2020, the FDA approved Epizyme’s drug tazemetostat (Brand name: Tazverik) to treat a rare type of solid tumor called epithelioid sarcoma. Tazemetostat targets the epigenetic enzyme EZH2, which is strongly linked to several cancer types. Now, Epizyme is seeking accelerated approval for tazemetostat to treat a common form of blood cancer called follicular lymphoma, and has clinical trials running for several additional cancer types. Cancer is a genetic disease that causes unrestrained cell proliferation. Typically, chemotherapies treat cancer by [more…]

WIE-logo-icon

If you like reading our articles…

Join our e-newsletter! Stay up-to-date with our weekly posts on epigenetics and health, nutrition, exercise, and more.